Harald Reinhart
Corporate Officer/Principal en ZAI LAB LIMITED .
Fortuna: 85 380 $ al 31/03/2024
Cargos activos de Harald Reinhart
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
ZAI LAB LIMITED | Corporate Officer/Principal | 01/01/2017 | - |
Historial de carrera de Harald Reinhart
Antiguos cargos conocidos de Harald Reinhart.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Shionogi, Inc.
Shionogi, Inc. Pharmaceuticals: MajorHealth Technology Part of Shionogi & Co., Ltd., Shionogi, Inc. is a pharmaceutical company based in Florham Park, NJ. Since 1878, the private company has been utilizing science to address health challenges and has discovered several novel antibiotics and medications for HIV and influenza. Shionogi conducts ongoing research into established products and new antibiotic compounds, as well as developing an investigational antiviral for COVID-19. The company is committed to pursuing discovery through partnerships, including collaboration with scientists through investigator-initiated research. Shionogi is dedicated to advancing the greater good by developing, partnering, and commercializing medicine to treat serious unmet medical needs in infectious disease and other areas of high medical need including neurology and cardiovascular disease. Nathan McCutcheon has been the CEO of the company since 2019. | Corporate Officer/Principal | - | - |
Formación de Harald Reinhart.
Julius-Maximilians-Universität Würzburg | Doctorate Degree |
Estadísticas
Internacional
Alemania | 2 |
Estados Unidos | 2 |
China | 2 |
Operativa
Corporate Officer/Principal | 2 |
Doctorate Degree | 1 |
Sectorial
Health Technology | 3 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
ZAI LAB LIMITED | Health Technology |
Empresas privadas | 1 |
---|---|
Shionogi, Inc.
Shionogi, Inc. Pharmaceuticals: MajorHealth Technology Part of Shionogi & Co., Ltd., Shionogi, Inc. is a pharmaceutical company based in Florham Park, NJ. Since 1878, the private company has been utilizing science to address health challenges and has discovered several novel antibiotics and medications for HIV and influenza. Shionogi conducts ongoing research into established products and new antibiotic compounds, as well as developing an investigational antiviral for COVID-19. The company is committed to pursuing discovery through partnerships, including collaboration with scientists through investigator-initiated research. Shionogi is dedicated to advancing the greater good by developing, partnering, and commercializing medicine to treat serious unmet medical needs in infectious disease and other areas of high medical need including neurology and cardiovascular disease. Nathan McCutcheon has been the CEO of the company since 2019. | Health Technology |
- Bolsa de valores
- Insiders
- Harald Reinhart
- Experiencia